Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Change in Interest Receivables (2022 - 2025)

Historic Change in Interest Receivables for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $485.0.

  • 60 Degrees Pharmaceuticals' Change in Interest Receivables fell 8864.7% to $485.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$594.0, marking a year-over-year decrease of 10724.83%. This contributed to the annual value of $23604.0 for FY2024, which is 10186.54% up from last year.
  • 60 Degrees Pharmaceuticals' Change in Interest Receivables amounted to $485.0 in Q3 2025, which was down 8864.7% from $1025.0 recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Change in Interest Receivables peaked at $158346.0 during Q3 2023, and registered a low of -$856914.0 during Q3 2022.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Change in Interest Receivables value was $790.0 (recorded in 2024), while the average stood at -$211298.8.
  • Its Change in Interest Receivables has fluctuated over the past 5 years, first skyrocketed by 65794.19% in 2024, then tumbled by 261011.38% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Change in Interest Receivables (Quarter) stood at -$629868.0 in 2022, then skyrocketed by 100.37% to $2342.0 in 2023, then soared by 657.94% to $17751.0 in 2024, then crashed by 97.27% to $485.0 in 2025.
  • Its Change in Interest Receivables stands at $485.0 for Q3 2025, versus $1025.0 for Q2 2025 and -$19855.0 for Q1 2025.